VRP25 Jun 2019 08:09
Well adding personnel is great, so must feel confident going forward
LONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Verona Pharma’s first-in-class product candidate, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).